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An association between papillomaviruses and epithelial malignancies had al-
ready been proposed by the 1970s; Dr. Harald zur Hausen was one of the first to 
hypothesize that human papillomaviruses (HPV) might be the cause of certain 
cancers. In 1983 and 1984 he was able to isolate two types of HPV genomes 
from cervical cancer samples – HPV-16 and HPV-18. For his ground breaking 
discovery he was awarded the Nobel Prize in Physiology and Medicine in 2008. 
After discovering the link between infection with certain subtypes of HPV and 
cancer, papillomaviruses have been intensively studied, resulting in new infor-
mation about the viral DNA replication, transcription, maintenance and onco-
genicity of papillomaviruses and their genes. In 2006, the first vaccine against 
cancer was introduced – a preventative vaccine against HPV. Nevertheless, sci-
entists have continued to study the molecular aspects of papillomavirus func-
tions as millions of people are and likely will be infected and are therefore at 
risk of acquiring cancer. The pursuit of identifying novel antivirals continues 
with the objective of inhibiting viral gene expression, certain steps of DNA 
replication or segregation, thereby eliminating the infection. Elucidating the 
mechanisms of cellular transformation and oncogenesis induced by the E5, E6 
and E7 viral oncoproteins may reveal novel antiviral targets for treating cervical 
cancer.  
A suitable model system is required to analyze the different aspects of a 
studied phenomenon. For a long period of time, the model system for papillo-
mavirus molecular biology was based on bovine papillomavirus type 1 (BPV-1). 
For BPV-1, the suitable cellular system is based on the mouse tumor cell line 
C127, where establishment of viral infection, initiation of DNA replication, 
persistence of the episomal genome, transcription, segregation and cellular 
transformation have been studied. This model system has provided most of the 
current information on viral genome features, viral genes, mechanisms of tran-
scription, gene expression, DNA replication and segregation as well as cellular 
transformation by BPV-1.  
There are also model systems described for HPV; however, until recently, a 
similar robust cellular system was lacking for HPV (Chow 2015). Thus, there 
was no good platform on which to investigate molecular mechanisms of the 
virus and that could also become the basis for screening antivirals. In this thesis, 
I refer to data that use the human osteosarcoma-derived cell line U2OS, as this 
cellular platform supports the replication different subtypes and genera of HPV 
genomes. Our studies have shown that viral DNA replication, early gene tran-
scription, splicing and other functions reflect the natural molecular mechanisms, 
as these exist during natural viral infection of primary keratinocytes. The only 
exceptions that we currently cannot reconstruct in U2OS cells are expression of 
late capsid proteins and assembly and maturation of infectious viral particles. 
After discovering the potential of the cellular system for HPV genome-level 
studies, our workgroup has extensively used this to characterize the molecular 
mechanisms of high and low risk mucosal HPVs and cutaneous HPVs. Some of 
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these studies are included in my thesis. In particular, I focus here on describing 
the molecular mechanisms and factors of clinically important oncogenic human 
papillomavirus HPV-18. In these studies, we described the HPV-18 transcrip-
tion map in U2OS cells. In addition, the thesis includes the characterization of 
specific elements and factors required for the maintenance and latency of the 




2. LITERATURE OVERVIEW 
2.1. General introduction to papillomaviruses 
The Papillomaviridae (PV) family consists of large group of DNA viruses in-
fecting a wide variety of vertebrates. PVs that are able to infect humans are 
defined as human papillomaviruses (HPVs). Over 200 HPV subtypes have been 
identified from genetic information obtained from patient epithelial tissue sam-
ples, and nearly 140 animal Papillomaviruses are listed in the Papillomaviruse 
Episteme (PaVE) database. Furthermore, the recent implications of next gener-
ation sequencing have enabled the discovery of several new Papillomavirus 
genotypes from asymptomatic tissue samples that would otherwise have been 
undetected or could not be cloned due to their low copy number (Eklund, 
Forslund et al. 2014) (Arroyo, Smelov et al. 2013). Newly discovered genotypes 
are constantly uploaded onto the PaVE database and verified by the Interna-
tional Papillomavirus Reference Center (Bzhalava, Eklund et al. 2015).  
Papillomaviruses infect cutaneous and mucosal epithelia and are associated 
with several malicious diseases – cervical cancer, oropharyngeal cancers, penile 
cancer, anal cancer in mucosal epithelia and squamous cell carcinoma (SCC), 
actinic keratosis (AK) and keratoacanthoma (KA) in cutaneous epithelia 
(Walboomers, Jacobs et al. 1999) (Asgari, Kiviat et al. 2008) (Harwood, 
Surentheran et al. 2004) (Mackintosh, de Koning et al. 2009) (Forslund, 
DeAngelis et al. 2003) (IARC 2007). Papillomaviruses are usually classified as 
high-risk and low-risk PVs, depending on their association with malignancies. 
Papillomaviruses are also responsible for benign tumors, such as genital warts 
or condylomas that are mainly due to infection with low-risk HPV 6 and 11. 
HPV DNA has been found in approximately 99% of cervical cancer lesions; 
however, in condylomatas, the number of HPV-positive samples had been ap-
proximately 96%, providing evidence that HPV-independent condylomas exist 
(Arroyo Muhr, Bzhalava et al. 2015). However, new metagenomic sequencing 
technologies have challenged the hypothesis of the existence of papillomavirus-
negative condylomata, as deep sequencing has detected HPV in almost all con-
dylomata biopsies (Johansson, Bzhalava et al. 2013) (Arroyo Muhr, Bzhalava et 
al. 2015). As HPV-16 and HPV-18 are known to be the cause of the absolute 
majority of cervical cancer cases, these viruses can be considered some of the 
strongest carcinogens (Burd 2003).  
The current therapies for treating HPV infections primarily involve surgery 
or cryotherapy for the excision or destruction of the infected tissue, respec-
tively. Although effective in many cases, these techniques are invasive and 
complicated, especially in facial and genital regions. Non-surgical treatments 
involve the topical administration of immunomodulators, such as imiquimod or 
podophyllin. However, the efficacy of non-specific immunotherapy is limited, 
and the rate of recurrence is relatively high, especially in immunocompromised 
patients (Scheinfeld and Lehman 2006). A more effective approach has been to 
prevent viral infection by the development of vaccines. In 2006, Cervarix and 
14 
 
Gardasil were approved as preventive HPV vaccines, initially covering 4 HPV 
subtypes (6, 11, 16, 18). In 2014, the FDA approved the 9-valent HPV vaccine 
Gardasil-9 that protects against up to 90% of all cervical cancer-causing HPV 
types (Siddiqui and Perry 2006) (Schmiedeskamp and Kockler 2006) (Gizzo, 
Noventa et al. 2013). Nevertheless, there is an unmet medical need for HPV 
antivirals to combat the virus in already infected people. Thus, as not all vac-
cination programs include the HPV vaccine, millions of people are diagnosed 
with HPV infections every year.  
Very limited numbers of anti-HPV drugs have been found. These few exam-
ples include inhibitors for ATPase activity of the viral replication protein E1, 
inhibitors for the interaction of viral replication proteins E1-E2, and compounds 
targeting the oncoproteins E6 and E7, which are reviewed in (D'Abramo and 
Archambault 2011). For these compounds, which have been identified mainly 
by biochemical assays in vitro and/or by surrogate cell-based assays, the antivi-
ral effects are generally weak and are usually specific to particular types of 
HPVs. The development of relevant cellular model systems and the description 
of viral mechanisms of action are key for setting up efficient screening for anti-
virals that can be used to cure existing viral infections. 
 
 
2.2. The papillomavirus life cycle 
The papillomavirus life cycle is a complex process; it takes advantage of physi-
cal injury to the epithelial tissue, interacting intensively with the host cell to 
ensure its productive life cycle. Simultaneously, it activates the appropriate 
countermeasures to avoid an antiviral response from the host. In this chapter,  
I have dissected the viral life cycle into three distinct sections: (i) Mechanism of 
viral entry to the host cell; (ii) Establishment of infection; (iii) Host differentia-
tion and productive phase of the PV.  
 
 
2.2.1. Viral entry 
Papillomaviruses infect epithelial tissues, and their life cycle is linked to the 
differentiation of epithelial cells. For entering the epithelium, microinjury of the 
epithelial tissue is required for viral particles to reach and attach to the basement 
membrane (BM). The receptors responsible for viral particle binding are com-
prised of heparan sulfate proteglycan (HSPG) and laminin 5, which are compo-
nents of the extracellular matrix (ECM). Virion affinity for these receptors ena-
bles the guidance of virions to the basal proliferating epithelial layer of 
keratinocytes, of which infection is targeted (Culp, Budgeon et al. 2006) (Culp, 
Budgeon et al. 2006). After binding of the virions to the basal membrane, a 
series of conformational changes is triggered within the viral particles that in-
duces the cleavage of L2 by furin-PC5/6, after which the virions attach to a 
receptor on proliferating basal epithelial cells, which are permissive for infec-
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tion (schematically represented in Fig. 1) (Kines, Thompson et al. 2009). The 
wound generated in the epidermis induces the proliferation and migration of 
basal keratinocytes with mitotic capability to heal the wound. The presence of 
mature HPV virions capable of infecting the proliferating cells would grant the 
right cellular target for HPV. Studies have shown that only the epithelial cells 
proximal to the BM are mitotic (Blanpain and Fuchs 2006), and papilloma-
viruses are only able to infect cells that are in M phase (Pyeon, Pearce et al. 
2009). Thus, the targeting of a specific period of the cell cycle assures that viral 
genome replication will be initiated and that infection may be established.  
The entry of the virus by endocytosis of clathrin-coated vesicles is itself a 
slow process, with viral disassembly detected 6-8 h post-entry (Day, Lowy et al. 
2003) (Day, Baker et al. 2004). Approximately 24 h post-infection, the viral 
genome can be found in the nucleus. During transport of the viral genome, the 
minor viral capsid protein L2 plays an additional significant role in granting 
efficient infection. After furine cleavage, the C-terminal fragment of the L2 
protein acts as a vehicle for efficient release from the endosome and also 
transport to the nucleus. This has been confirmed by the fact that both the  
C-terminus of L2 and the genome can be detected in the nucleus. At the same 




2.2.2. Establishment of infection 
After entry of the viral genome into the nucleus of the cell, the early promoters 
of HPV are activated, triggering viral early gene expression and leading to the 
initial replication of viral genomes in the S- and G2 phases of the cell cycle. 
Viral E1 and E2 proteins are necessary and sufficient to replicate and maintain 
viral genome as an episome in dividing cells (Ustav and Stenlund 1991) (Ustav, 
Ustav et al. 1991) (Ustav, Ustav et al. 1993) (Chiang, Ustav et al. 1992) 
(Wilson, West et al. 2002). The viral transforming proteins E6 and E7 are ex-
pressed from the viral genome, and there is an increase in the number of cells 
harboring viral genomes shortly after infection. This is triggered by E6- and E7-
induced cellular proliferation of the infected cells in the early phase of the in-
fection (Doorbar 2005). Due to the initial transient amplificational DNA 
replication in basal cells, viral infection can be established, after which HPV 
maintains itself at a relatively low copy number of 20–200 copies per cell, and 
all viral early genes are expressed at a low level (Doorbar, Quint et al. 2012). 
The initial amplificational replication and stable maintenance is further dis-
cussed in the respective chapters of this thesis. 
 
 
2.2.3. Productive phase  
Keratinocytes normally initiate and undergo terminal differentiation after mi-
grating from the basal to the suprabasal cell layers, after which they normally 
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no longer enter S-phase. However, in virus-infected cells in the differentiating 
epidermis, the expression of oncoproteins still induces activation of the host 
replication machinery and thereby viral DNA replication (Banerjee, Genovese 
et al. 2006; Banerjee, Wang et al. 2011). Viral oncoproteins act via the associa-
tion with cell cycle regulators and are positive stimulators of the cell cycle 




Figure 1. Simplified view of stratified mucosal and cutaneous epithelium and viral gene 
expression dependent on the state of the virus-infected cell. PVs cannot infect keratino-
cytes directly; rather, viral capsids have to undergo conformational changes at the basal 
membrane (BM) before particles become infectious. 
 
 
Virus-infected cells migrate to the suprabasal level and enter the differentiation 
phase. During that process, the change in the cellular microenvironment yields 
change of the splicing pattern and expression of viral proteins, amplification of 
viral genome and eventually results in the production of the viral capsid pro-
teins, packaging of the viral particles as the virus-infected cell reaches the final 
layers of terminally differentiated epithelial cells (Cheng, Schmidt-Grimminger 
et al. 1995) (Johansson and Schwartz 2013). Before the production of late pro-
teins and assembly of viral particles, the viral copy number is increased during 
the second amplificational replication stage. In uninfected cells, the cell cycle is 
retarded. In HPV-infected cells, the viral oncogenes E6 and E7 are capable of 
overcoming this block; they induce S-phase to replicate DNA through inducing 
endoreduplication without cellular division (Cheng, Schmidt-Grimminger et al. 
1995).  
Papillomaviruses activate the ATM DDR pathway that acts through three 
different branches - p53/p21, CHK2/CDC25 and NBS1/SMC1 (Yazdi, Wang et 
al. 2002) (McKinney, Hussmann et al. 2015). PV amplification has been shown 
to be mediated through the interaction of these DNA damage response path-
ways, and this is discussed further in the replication overview chapter of this 
thesis (Moody and Laimins 2009) (Gillespie, Mehta et al. 2012) (Sakakibara, 
Mitra et al. 2011) (Kadaja, Sumerina et al. 2007) (McKinney, Hussmann et al. 
2015). To amplify the viral DNA in the second amplification phase, all viral 
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early genes are expressed, including E4 and E5 (Ozbun and Meyers 1998) 
(Longworth and Laimins 2004).  
The viral genome is amplified by the cellular replication machinery, which is 
activated by E7 and directed at the viral origin by the E1 and E2 proteins. 
Throughout the viral life cycle, promoter usage and splice site variation regulate 
the expression of early proteins. To amplify the viral DNA in the second ampli-
ficational phase, an increase in the level of E1 and E2 proteins is required. The 
exact mechanism for the upregulation of E1 and E2 protein expression is not 
well understood, but a possibility is that a slight increase of promoter activity 
might trigger the increase of early gene expression, thereby also increasing 
replication by positive feed-back – the newly synthesized viral genomes would 
act as templates for the expression of E1 and E2 that would facilitate the addi-
tional amplification of viral DNA (Doorbar 2005). 
As the cell migrates to the upper level of epithelial tissue, the early poly-
adenylation site of HPV is repressed, viral mRNA is transcribed through the L2 
and L1 ORF, and the late polyadenylation site is used to generate mRNA to 
express structural proteins L1 and L2 to encapsulate the amplified viral ge-
nomes (Doorbar 2005) (Doorbar 2006). During the initial and stable infection 
phase, the late polyadenylation site is repressed by cellular factors as they are 
expressed in the basal layer cells (Somberg, Zhao et al. 2008) (Johansson and 
Schwartz 2013). hnRNP family proteins have been shown to be responsible for 
the inhibition of pAL, and repression of hnRNP has been shown to activate the 
expression of L1 and L2 (Zhao, Rush et al. 2004) (Oberg, Fay et al. 2005). 
More recently, RALYL, a protein that belongs to the hnRNP C family, has been 
shown to activate late gene expression (Dhanjal, Kajitani et al. 2015). E2 re-
cruits L2 protein to the viral genome, after which L1 and L2 form the viral cap-
sid in the nucleus. The papillomavirus genome is encapsulated within a capsid 
that contains 360 copies of L1 protein and 72 copies of L2 protein. Viral matu-
ration occurs in the upper most layer of the epithelium within terminally differ-
entiated keratinocytes. The change from the reducing to oxidative environment 
enables accumulation of disulfide bonds between L1 proteins, thereby resulting 
in extremely stable viral particles (Finnen, Erickson et al. 2003) (Buck, 
Thompson et al. 2005). E4 protein seems to play a role in viral exit from cells as 
E4 disrupts the keratin structure by assembling into amyloid fibers, thereby 
enabling infectious viral particles to exit the cells (McIntosh, Martin et al. 2008) 
(Wang, Griffin et al. 2004) (Brown, Kitchin et al. 2006). 
 
  
2.3. Genomic organization of  
papillomaviruses and viral proteins 
Papillomaviruses have a circular double-stranded DNA genome that is ap-
proximately 8 kb in size. The genome can be divided into three regions – early 
(E), late (L) and noncoding long control regions (LCR). The early region of 
papillomaviruses encodes seven common open reading frames (E1, E2, E4, E5, 
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E6, E7 and E8). The late region encodes two structural proteins L1 and L2  
(Fig. 2). The LCR does not encode any protein coding sequences; however, it 
contains crucial cis-elements required for viral DNA replication, transcription 
and stable maintenance. All ORFs are encoded from one strand and are structur-
ally and functionally conserved between different HPV subtypes. As papilloma-
virus mRNAs are polycistronic, it has been difficult to identify all minor 




Figure 2. Schematic representation of the HPV-18 genome. The LCR with replication 
origin and E2BS is represented at the top. The early (E) and late (L) gene ORFs are 
marked. The positions of early and late promoter and polyadenylation sites are marked 
with arrows. Adopted from (McBride and Jang 2013). 
 
 
Two viral proteins, E1 and E2, are the cornerstones of viral DNA replication 
and play a crucial role throughout the viral lifecycle. E1 is expressed from a 
polycistronic mRNA and is conserved among all Papillomaviruses with main 
functions of replication origin recognition and viral ATP-dependent helicase 
activity (Remm, Remm et al. 1999) (Ustav and Stenlund 1991) (Ustav, Ustav et 
al. 1991; Chiang, Ustav et al. 1992) (Sun, Thorner et al. 1990) (Bergvall, 
Melendy et al. 2013). Recent studies have shown novel functions for E1. The 
overexpression of E1 protein can cause double-strand DNA breaks (DSB), ge-
nomic instability and activate the DNA damage response (DDR) pathways 
(Sakakibara, Mitra et al. 2011) (Reinson, Toots et al. 2013) (Fradet-Turcotte, 
Bergeron-Labrecque et al. 2011) (Kadaja, Sumerina et al. 2007).  
The role of E2 protein in the papillomavirus life cycle can be considered as 
very universal; E2 acts as a major viral transcriptional regulator, viral DNA 
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replication initiation protein, factor responsible for segregation and for viral 
particle assembly (McBride 2013). BPV-1 E2 is a strong transcriptional activa-
tor, while the E2 proteins of the alpha-genus subtypes, such as HPV-16 and 
HPV-18, are considered transcriptional repressors of the promoter for express-
ing the viral oncogenes E6 and E7 (Knipe 2007). E2 protein also binds with E1, 
stabilizes the protein and increases the specificity of E1 for recognizing the 
replication origin (Stenlund 2003). The third major function of the E2 protein is 
its ability to tether the viral genome to the mitotic chromatin, thereby partici-
pating in the relatively equal distribution of viral genomes to daughter cells 
(McBride 2013). A number of potential cellular partners have been described 
for E2, but certain differences have been identified between different subtypes. 
The bromodomain family protein Brd4 is probably the most intensively studied 
cellular partner, playing a role as a transcriptional modulator as well as part of 
the cellular tethering complex (You, Croyle et al. 2004) (Ilves, Maemets et al. 
2006) (McPhillips, Ozato et al. 2005) (Jang, Kwon et al. 2009) (Wang, Helfer et 
al. 2013). Another cellular protein ChlR1 has been shown to play an important 
part in the stable maintenance of viral genomes upon binding with E2 (Parish, 
Bean et al. 2006). Mitosin like kinase Mklp2 and TopBP1 have also been sug-
gested as cellular partners for stable maintenance of the viral genome (Yu, Peng 
et al. 2007) (Donaldson, Boner et al. 2007). The role of E2, the truncated forms 
of E2 and its interaction partners in the viral life cycle are discussed in more 
detail in further chapters of this thesis.  
E4 protein (E1ˇE4) expression is dependent on KC differentiation, and it is 
mainly expressed in the upper layers of the epithelium. E4 protein has been 
described to play important roles in preparing viral particle exit. For example, a 
link has been reported between blocking the cell cycle and disrupting cyto-
keratins by forming amyloid filaments (Doorbar, Ely et al. 1991) (Doorbar 
2013). E4 interacts with keratin, and their structures are modified by different 
kinases as the cell differentiation, thereby enhancing E4’s association with 
cellular keratin (McIntosh, Laskey et al. 2010) (Doorbar 2013). In the final 
differentiation stages, E4 is cleaved by Calpain and forms the amyloid fibers for 
disruption of the cellular cytokeratins that aid viral exit from the cells (Khan, 
Davy et al. 2011). As E4 is easily detected by immunostaining biopsy materials, 
it could serve as a possible biomarker for viral infection. 
E5 proteins are short hydrophobic transmembrane proteins and are consid-
ered to hold transforming activities, although their role in productive infection 
is poorly defined. Most information about E5 has been derived from BPV-1 and 
HPV-16 studies (DiMaio and Petti 2013). The E5 protein of BPV-1 has been 
shown to induce transformation by binding directly and activating the PDGF-
beta receptor (Petti, Nilson et al. 1991) (Petti and Ray 2000; Talbert-Slagle and 
DiMaio 2009) (Edwards, Xie et al. 2013). HPV E5 proteins have been shown to 
possess a low transforming ability. HPV-16 E5 does not have sequence similar-
ity with BPV-1 E5; instead of binding the PDGF-beta receptor, it binds epider-
mal growth factor (EGF) to induce cellular growth and proliferation (Straight, 
Hinkle et al. 1993; Auvinen, Crusius et al. 1997) (Genther Williams, Disbrow et 
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al. 2005). Although the transforming ability of E5 in vitro is low, it still seems 
to play a role in carcinogenesis as mouse studies have shown E5 to contribute to 
the generation of neoplastic cervical cancer (Maufort, Shai et al. 2010). HPV-16 
E5 also plays a role in avoiding the activation of apoptotic pathways by im-
pairing TRAIL- and FasL-mediated apoptotic pathways (Kabsch, Mossadegh et 
al. 2004) (Kabsch and Alonso 2002). In the basal layer, E5 is considered to play 
a role in the immune evasion of HPV-infected cells. E5 helps to downregulate 
MHC/HLA class I by the alkalinization of endomembrane compartments 
(Schapiro, Sparkowski et al. 2000) (Stanley, Pett et al. 2007) (Ashrafi, 
Haghshenas et al. 2006).  
The other two viral oncoproteins are E6 and E7, which are expressed from a 
polycistronic mRNA directed from the early viral promoter. The E6 proteins are 
comprised of approximately 150 amino acids and contain two zinc-fingers that 
are flanked by the N- and C-terminal domains (Howie, Katzenellenbogen et al. 
2009). E6 is one of the tumor-inducing oncoproteins of HPV. The HPV E6 
oncoprotein binds to a cellular protein of 100 kD, termed E6-associated protein 
(E6-AP). The E6/E6-AP complex specifically binds to p53, resulting in the 
rapid ubiquitin-dependent degradation of p53 (Huibregtse, Scheffner et al. 
1991). E6AP is unable to bind p53 without the interaction of E6 with its  
N-terminal domain. (Huibregtse, Scheffner et al. 1993) (Huibregtse, Scheffner 
et al. 1993). This process helps the virus to prevent cell cycle block and in-
duction of apoptotic pathways. E6 has a number of other interaction domains 
and partners (White, Kramer et al. 2012). In addition to inactivating p53 and 
blocking apoptosis, it has been shown to play a role in the evasion of the 
immune response by interacting with IRF-3 and TLR-9 (Ronco, Karpova et al. 
1998) (Hasan, Bates et al. 2007). Furthermore, an interaction with proteins 
responsible for G protein modulation, and therefore cell growth, has been 
demonstrated (Howie, Katzenellenbogen et al. 2009).  
The E7 protein is the third oncoprotein of HPV; similarly to E6, E7 also 
contains a zinc-finger. It is hypothesized that E6 and E7 may have derived from 
a duplication event of one of the core motifs (Cole and Danos 1987). E7 is en-
coded by all HPVs, but their differences in oncogenicity are due to the binding 
affinity of E7 with the pRb family proteins. E7 inhibits the retinoblastoma 
(pRB) family proteins, thereby releasing and activating the transcription factor 
E2F that drives the expression of S-phase genes (Moody and Laimins 2010). 
This enables papillomavirus DNA replication in differentiating suprabasal cells.  
L1 and L2 are the two structural proteins expressed by papillomaviruses and 
are conserved throughout the different subtypes. Together they form the viral 
capsid that is composed of 360 copies of L1 protein and 72 copies of L2 protein 
(Finnen, Erickson et al. 2003). The late proteins encapsulate the viral genomes 
and also play a key role in viral entry; they are important targets of inducing 
sterilizing immunity against the virus (Richards, Lowy et al. 2006) (Conway 




 2.4. E2 proteins – characteristics and functions 
The E2 protein is an essential regulatory protein that is expressed by all papil-
lomaviruses. It plays a role in viral transcriptional regulation, DNA replication 
and the segregation of viral genomes to daughter cells as well in late phases of 
the virus infection cycle. In addition, several truncated versions of E2 protein 
are expressed that have been shown to participate in the regulation of different 
aspects of the papillomavirus life cycle. All E2 proteins carry the C-terminal 
DNA binding dimerization domain and bind to the specific 12bp palindromic 
motif, -5’-ACCGNNNNCGGT-3’, that is found several times in the LCR. The 
full-length E2 protein consists of three structural domains. The N-terminal 
transactivation (TA) domain has been shown to contain many of the interaction 
domains with cellular interaction partners and is connected with the C-terminal 
DNA-binding domain (DBD), responsible for binding to the viral binding motif. 
The two domains are connected by a flexible hinge region, as schematically 
represented in Fig. 3 (Giri and Yaniv 1988) (McBride, Byrne et al. 1989) 




Figure 3. Schematic representation of E2 protein with its functional domains. 
 
 
Many papillomaviruses have the ability to encode truncated versions of E2 
protein that mostly contain the DBD, hinge and sometimes residues from the 
TA domain (Chiang, Broker et al. 1991) (Lace, Anson et al. 2008) (Lace, 
Ushikai et al. 2012) (Lambert, Hubbert et al. 1989) (Toots, Mannik et al. 2014). 
In general, these truncated versions have been characterized as transcriptional 
and replicational repressors; however, a certain function has not been allocated 
to all isoforms. As E2 is usually present in the cell as a dimer, it has been shown 
that E2 heterodimers with the truncated E2 versions are mostly prevalent. 
Studies in our group have shown that such heterodimers are active as transcrip-
tional regulators and are effective in the initiation of DNA replication but not 
for stable maintenance and segregation of viral DNA (Kurg, Tekkel et al. 2006) 
(Kurg, Uusen et al. 2009) (Kurg, Uusen et al. 2010). One of the most frequently 
described variants of E2 protein is E8^E2C (Stubenrauch, Hummel et al. 2000). 
The E8^E2C protein is generated by splicing of a transcript that contains a short 
exon located in the E1 ORF that encodes E8 peptide fused with the E2 ORF at 
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an acceptor site to encode E8^E2C. All papillomaviruses have been shown to 
potentially encode truncated E2 transcripts that contain the E2C domain, the 
hinge region and a part of a sequence of an upstream ORF (McBride 2013). 
E8^E2C has been described as an inhibitor of viral genome replication for a 
number of high-risk PVs in undifferentiated cells. There are several ways that 
this protein can repress viral functions. First, this protein carries no transcription 
activation domain, and it can compete with full-size E2 for binding at E2 bind-
ing sites. Second, this protein can form heterodimers with all E2 proteins and 
can thus eliminate or acquire certain specific functions. Third, E8^E2C uses the 
E8 peptide to recruit repressor complexes to the viral DNA (Ammermann, 
Bruckner et al. 2008) and thereby acts as a repressor of the viral early promoter 
and an inhibitor of E1/E2-dependent viral origin replication (Lace, Anson et al. 
2008) (Zobel, Iftner et al. 2003). The E8^E2C contains an 11 amino acid 
peptide that is the shortest known protein sequence to target the cellular nuclear 
matrix (NM) (Sankovski, Karro et al. 2015). Mutational analysis has shown that 
elimination of expression of the E8^E2C results in overreplication of PV ge-
nomes throughout the viral life cycle (Ammermann, Bruckner et al. 2008) 
(Lace, Anson et al. 2008) (Kurg, Uusen et al. 2010) (Straub, Dreer et al. 2014). 
 
 
2.5. HPV transcription and the role of E2  
As the virus enters the epithelial cells of the basal layer, the viral genome mi-
grates to the cell nucleus, after which the virus genome has to link and adapt 
itself to the cellular regulatory circuit to become biologically active. To enable 
this, the early viral genes have to be expressed using the main early promoter 
P102 for HPV-18 (Fig. 4) and p97 for HPV-16. All species of mRNAs initiated 
from this promoter are polycistronic, use the early polyadenylation site (pAE) 
and have the potency to translate different early viral proteins (Graham 2010) 
(Johansson and Schwartz 2013). The pAE in papillomaviruses is located before 
the late coding region, and the pAL is located in the upstream region of the 
LCR after the late coding region. During the early stages of differentiation, the 
mRNAs are still polyadenylated via the pAE; as the cell differentiates to the 
granular layer of the epithelia, pAE activity is suppressed, and the mRNA 
readthrough reaches the L2 and L1 region, where the mRNA is polyadenylated 
at the late polyadenylation site (pAL) (Doorbar, Parton et al. 1990) (Grassmann, 
Rapp et al. 1996) (Milligan, Veerapraditsin et al. 2007).  
The regulation of promoter and polyadenylation activity is heavily depend-
ent on the cellular transcription factors, and as the cell enters differentiation, the 
composition of cellular regulators is also alternated. For example, it was re-
cently shown that the heterogeneous nuclear ribonucleoprotein C interacts with 
HPV-16 3’UTR and thereby activates late L1/L2 gene expression. The levels of 
hnRNP are very low in basal keratinocytes but are increased in upper differenti-
ated layers of the skin (Dhanjal, Kajitani et al. 2015). Although viral transcrip-
tion is heavily dependent on cellular regulators, a major role is played by viral 
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regulators that either directly manipulate transcription or act as interaction part-




Figure 4. The HPV-18 genome schemata with marked promoter regions and positions 
of the early and late polyadenylation cleavage site. 
 
 
One of the major viral transcriptional regulators of papillomaviruses is the E2 
protein. A screen mapping E2 and host interaction partners of 12 HPV geno-
types revealed that E2 interacts with highly interconnected cellular proteins. 
The proteins and interactions regulate a number of cellular processes – tran-
scriptional regulation, apoptosis, RNA metabolism, ubiquitination and intracel-
lular transport (Muller, Jacob et al. 2012). Interestingly, the interactome of 
different cellular transcription factors with E2 is quite heterogeneous among the 
different genotypes. Ten transcription factors, including Brd4, were found to be 
targeted by all E2 proteins, and most probably play an important role in tran-
scriptional regulation for all 12 studied genotypes (Muller, Jacob et al. 2012). 
E2 has been shown to recruit cellular factors to the viral genomes, which then 
act as either activators or repressors of viral transcription and can also partici-
pate in replication or viral genome tethering processes (Ilves, Maemets et al. 
2006) (McPhillips, Oliveira et al. 2006) (Parish, Bean et al. 2006) (Wang, 
Helfer et al. 2013). E2 proteins bind to their specific E2BSs located in the viral 
genome and act either as activators or repressors depending on the related loca-
tion of the BS and the interacting cellular proteins. Mucosal HPV types have 
E2BSs located proximal to the early promoter, and E2 binding to these sites 
represses transcription. In cutaneous HPV genomes, E2BSs are located distal 
from the early promoter, and E2 binding to its BSs have been shown to act as 
transcriptional activators (Guido, Zamorano et al. 1992). In the case of mucosal 
HPV types, E2-mediated repression of the early promoter has been demon-
strated, resulting from the fact that the cellular transcription factor binding sites 
are partially overlapping or are within near proximity of the specific E2BS and 
interfere with each target protein binding. For example, when E2 is bound to the 
viral genome, the TBP and Sp1 are sterically blocked from binding to the viral 
genome (Thierry 2009) (Dong, Broker et al. 1994). However, E2-mediated 
repression of the early promoter is due to steric interference as well as E2 pro-
tein recruitment of a number of cellular transcriptional repressors to the viral 
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genome. E2 interacts with histone modulators, such as demethylase SMCX and 
the EP400 component of histone acetyltransferase complex (Smith, White et al. 
2010).  
A large number of cellular factors has been shown to interact with E2 pro-
teins that have pronounced roles in regulating different aspects of the viral life 
cycle, of which a large number are described as transcriptional repressors. 
(Muller and Demeret 2012) (Muller, Jacob et al. 2012). One of the major part-
ners of E2 is the cellular bromodomain protein Brd4 that has been shown to 
play a central role in both transactivation and repression (Ilves, Maemets et al. 
2006) (McBride and Jang 2013) (You, Croyle et al. 2004) (Wu and Chiang 
2007). Brd4 directs E2 by interacting with the TA-domain of the protein to 
transcriptionally active cellular chromatin (McPhillips, Ozato et al. 2005). Brd4 
is a component of the HPV-11 E2 transcriptional silencing complex that is re-
sponsible for repression of the E6/E7 oncoproteins promoter repression (Wu, 
Lee et al. 2006). E2 can also bind to the oncoproteins E6 and E7, resulting in 
modulation of their functions. E2 and E7 bind to each other through the hinge 
and zinc-binding domains, respectively, resulting in inhibition of E7-induced 
transformation and recruiting E7 to the mitotic chromosomes in later stages of 
mitosis (Gammoh, Grm et al. 2006) (Gammoh, Isaacson et al. 2009). E2 and E6 
have also been shown to interact directly through sequences located in the  
C-terminal domain of E2 and residues between aa28-31 of E6. E6 binding to E2 
limits viral replication but simultaneously elevates the transcriptional activity of 
E2 (Grm, Massimi et al. 2005). Studies have also shown that E2 can induce 
apoptosis through different pathways. E2 can induce apoptosis via binding to 
p53 and induce apoptosis in both HPV-transformed and non-transformed cells, 
and secondly, E2 can bind to the viral genome of HPV-transformed cells 
(Webster, Parish et al. 2000) (Parish, Kowalczyk et al. 2006). 
In addition to full length E2, the truncated forms of E2 have been shown to 
compete with full length E2 protein for binding to their respective binding sites, 
thereby repressing the functions of full length E2 protein. The most pronounced 
of these versions is E8^E2C, which has been shown to recruit cellular repressor 
complexes to the viral genome (Ammermann, Bruckner et al. 2008). The 
E8^E2C of HPV-31 has been described to interact with NcoR1/HDAC3, a his-
tone methyltransferase SETDB1 and TRIM28 protein to function as an inde-
pendent repressor domain (Powell, Smith et al. 2010) (Ammermann, Bruckner 
et al. 2008). 
 
 
2.6. HPV DNA replication  
Papillomaviruses exclusively infect cutaneous or mucosal keratinocytes, and 
they have adapted their life cycle to the stages of differentiation of epithelial 
cells. During normal epithelial homeostasis, keratinocytes exit the cell cycle and 
undergo terminal differentiation that ultimately leads to cell death. In contrast, 
papillomaviruses have evolved extensive mechanisms to manipulate the 
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infected cells and integrate their productive life cycle with cells going through 
differentiation. The papillomavirus DNA replication cycle in infected cells can 
be dissected into three modes – (i) the initial amplificational replication for 
propagation of the genome copy number during the establishment of infection 
in the host cell; (ii) stable maintenance replication to keep the genome copy 
number relatively constant during latency period, when viral DNA is spread 
into the progeny of the infected cell and; (iii) vegetative replication in the upper 
layer of the epithelium for large amplification of new viral genomes for package 




Figure 5. Representation of the three replicational phases of the papillomavirus ge-
nome. After viral genome entry into the nucleus, initial amplification is achieved by 
multiple rounds of viral DNA replication per cell-cycle, followed by stable maintenance 
replication that takes place in synchrony with the cellular DNA replication, resulting in 
doubling of DNA per cell cycle. When the host cell enters differentiation, then amplifi-




2.6.1. Initial amplificational replication and  
mechanism of viral DNA replication  
It is very difficult to study molecular mechanisms of viral genome replication in 
vivo using differentiating epidermis. For such studies, three-dimensional models 
of differentiating epidermis have been developed and used with several limita-
tions (Chow 2015). Most of the basic mechanistic studies about the function of 
papillomaviruses have been executed in model systems based on transformed 
cell lines. In these studies, papillomavirus DNA replication in the initiation 
phase has been considered to consist of both bi-directional theta-type and re-
combination-dependent replication modes (Orav, Geimanen et al. 2015). 
The E1 and E2 proteins have been shown to be the major viral trans factors 
for PV replication, as several studies have demonstrated that they are the only 
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viral proteins required for initiation and elongation of replication per se (Kuo, 
Liu et al. 1994; Sverdrup and Khan 1994) (Del Vecchio, Romanczuk et al. 
1992) (Chiang, Ustav et al. 1992). The viral replication origin is located in the 
LCR, and the minimal replication origin of HPV has been described to contain 
the E1BS flanked by two E2BSs (Lu, Sun et al. 1993) (Sverdrup and Khan 
1995) (Remm, Brain et al. 1992). The replication initiation process begins with 
the formation of the pre-replication complex (pre-RC) by E1/E2 complex for-
mation and traveling of the complex to the viral origin, where E1 initially binds 
the replication origin as a dimer (Mohr, Clark et al. 1990) (Frattini and Laimins 
1994) (Sedman and Stenlund 1995) (Masterson, Stanley et al. 1998). However, 
the replication initiation process itself is E2-independent, and cell-free replica-
tion studies have shown that the E2 is displaced from the complex after E1 has 
bound to the viral origin (Kuo, Liu et al. 1994). As the E1 specificity to its bind-
ing site is low, the role of E2 is crucial for recruiting E1 to the replication 
origin, and this is mainly due to the ability of E2 to simultaneously bind E1 and 
viral DNA, as seen from the first step in Fig. 6 (Seo, Muller et al. 1993) 
(Frattini and Laimins 1994). After the E2 is displaced from the complex, E1 
forms a double trimer (DT) to bind viral DNA and melt the DNA strands in 
origin (Fig. 6. Step 2). Then, the formation of a double hexameric (DH) helicase 
is possible with the presence of ATP hydrolysis (Fig. 6. Step3) (Sedman and 
Stenlund 1996) (Schuck and Stenlund 2005) (Sedman and Stenlund 1998). Only 
ssDNA can be bound within the hexameric ring of the E1 helicase, and the 
DNA binding hairpins of the hexamer form a spiral staircase, enabling the DNA 
to pass through the helicase as it rotates (Enemark and Joshua-Tor 2006). ATP 
hydrolysis occurs at the top of the staircase, and ADP is released in the bottom 
of the staircase. As the hairpin reaches the bottom of the staircase, it releases the 
bound ssDNA and is ready to bind new ATP as it moves to the top of the stair-
case and binds the new nucleotide.  
As papillomaviruses express only a limited number of proteins, they rely 
heavily on recruiting cellular factors for executing different mechanisms re-
quired for the viral life cycle. Viral DNA replication is not an exception, and 
efficient viral DNA replication relies on the appropriate partners, including the 
cellular DNA polymerases α and δ (Bergvall, Melendy et al. 2013) (Conger, Liu 
et al. 1999). Topo I is an ATP-independent protein that enables the modification 
of supercoiled DNA topology by reducing the torsional stress of the DNA. Pap-
illomavirus E1 interacts directly with Topo 1 at DBD, and this interaction in-
creases Topo1 activity (Clower, Fisk et al. 2006). At the same time, Topo 1 
enhances E1 binding to the origin and E1 oligomeric formation to functioning 
as a helicase. E1 DBD involves the interaction with the replication protein A 
(RPA) and the loading of RPA molecules to ssDNA during lagging strand syn-
thesis (Loo and Melendy 2004) (Hu, Clower et al. 2006). As the viral helicase 
rotates and progresses along the replicating DNA, E1-bound RPA molecules are 
directed proximally to the naked ssDNA molecules, enabling binding of RPA 
from E1 to the ssDNA. Only free RPA molecules are able to re-bind E1, as 
already ssDNA-bound RPA molecules have very low affinity for E1, probably 
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due to steric alterations (Loo and Melendy 2004). The α-primase DNA 
polymerase interacts using its p70 or p180 subunits with the helicase domain of 
E1. It plays a role in re-initiation of replication during synthesis of the lagging 
strand of viral DNA (Park, Copeland et al. 1994) (Bonne-Andrea, Santucci et al. 




Figure 6. Cartoon describing the initiation of viral DNA replication: unwinding of 
dsDNA and formation of the pre-RC. First, E2 recruits E1 to the viral origin (ori), after 
which the E1 double trimer (DT) is formed. The ori melting enables assembly of the E1 
double hexameric helicase (DH) and further recruitment of cellular DNA replication 
factors. Adopted from (Bergvall, Melendy et al. 2013). 
 
 
2.6.2. Stable maintenance replication 
After the initial rapid amplification of viral genomes, the virus is maintained in 
dividing basal and suprabasal cells at a relatively constant copy number. This is 
believed to be achieved by two functions of viral genome persistence: first, by 
slowing down the initiation of replication, resulting in approximately once per 
cell cycle replication, granting doubling of virus genome copies every cell cy-
cle; and second, by efficient segregation of the its extrachromosomal genome 
into daughter cells during the division of latently infected cells. 
Most information about the stable maintenance replication phase has been 
generated from BPV-1 studies. For BPV-1 in C127 cells, it has been demon-
strated that the viral genome replicates following a random mechanism of  
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initiation of replication during the stable replication phase (Gilbert and Cohen 
1987). For HPV, no definitive results have been published. Studies of the  
HPV-16 and HPV-31 mode of replication in W12 and CIN612 cells, respect-
ively, have indicated that HPV DNA replicates either by random-choice 
(CIN612) or by once-per-cell cycle (W12) mechanisms. However, when HPV-16 
and HPV-31 DNAs were separately introduced into the immortalized keratino-
cyte cell line NIKS, they both replicated randomly (Hoffmann, Hirt et al. 2006). 
These controversial results were interpreted such that papillomaviruses can 
infect two types of epithelial cells – stem-like cells and transiently amplifying 
cells and that differences observed in the replication modes between W12 and 
CIN612 are caused by the different nature of the host cells (Kim, Garner-
Hamrick et al. 2003; Hoffmann, Hirt et al. 2006). This explanation is highly 
speculative, and authors have not demonstrated that both cell lines, W12 and 
CIN612, actually carry the episomal copies of the virus. An alternative explan-
ation is that the virus genome is integrated in the W12 cells and therefore is 
independent of E1 and follows the once-per-cell cycle cellular DNA replication 
mode, while the HPV-31 positive cell line CIN612 carries the episomal viral 
genomes in the cells. HPV-16 genome integration in W12 cells has been 
demonstrated convincingly (Pett, Herdman et al. 2006).  
The BPV-1 E1 and E2 proteins are necessary for efficient maintenance repli-
cation of the viral genome (Ilves, Kadaja et al. 2003). It has also been suggested 
that in stable maintenance replication, papillomavirus genomes can replicate 
episomally and be maintained without any viral protein expression (Kim and 
Lambert 2002). One hypothesis is that E1 might be required only initially for 
establishing viral DNA in the nucleus and for vegetative replication but is not 
required for the maintenance phase (Egawa, Nakahara et al. 2012). This state-
ment contradicts the findings that the origin of replication for BPV-1, HPV-11 
and HPV-16 during stable episomal replication has been mapped into the LCR 
where the E1/E2 dependent replication origin is located, and 2D-gel electropho-
resis indicates that the same replication intermediates exist during the stable 
replication phase as during the E1/E2 dependent amplificational replication 
phase.  
The stable maintenance replication of the viral genome in proliferating cells 
is ultimately linked with effective segregation of the viral episomes into daugh-
ter cells. Several cellular partners in the segregation process have been identi-
fied, and the mechanisms of stable maintenance of viral genomes will be dis-
cussed further below.  
 
 
2.6.3. Vegetative viral DNA replication 
Vegetative HPV DNA replication, or the second amplificational replication, 
occurs as virus-infected keratinocyte migrate into the upper layers of the epi-
dermis and enter the differentiation path. During this phase, the cellular micro-
environment changes, including the expression of cellular miRNAs, inducing a 
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switch of viral gene expression, which is needed for viral exit from the cells 
(Gunasekharan, Hache et al. 2012) (Zheng and Wang 2011). It is crucial for the 
virus to amplify the genome copy number for efficient packaging of the genome 
into virions, which is possible after the production of viral late proteins. The 
exact mechanism of initiation and mode of HPV genome replication is still 
under study; however, a number of cellular cofactors have been described to 
play a role in this process.  
The fact that such a replicative phase exists is derived from the information 
of the change of viral DNA copy numbers (20–200) during replication of basal 
cells from the viral DNA copy number (100–1000) obtained from episome-
containing cervical cell lines. In the case of vegetative amplificational replica-
tion, there are studies showing that rolling circle replication might be used in-
stead of bidirectional theta type replication (Dasgupta, Zabielski et al. 1992) 
(Flores and Lambert 1997). Rolling circle replication (RCR) would allow more 
rapid synthesis of viral DNA molecules for encapsulating into virions without 
the need for initiation of replication for duplication of viral genomes, a prereq-
uisite for recombination-related replication (RDR) (Orav, Henno et al. 2013) 
(Orav, Geimanen et al. 2015). Nevertheless more data are required to clarify 
switching between replication modes as viral-infected cell enters differentiation. 
Our group has recently demonstrated that stable HPV DNA replication occurs 
in the S-phase, but in the case of increased E1 levels, viral DNA replication is 
extended to the G2 phase (Reinson, Henno et al. 2015). The ability to replicate 
also in G2 phase might be important from the virus perspective, as differenti-
ated cells are usually blocked in G2 (Wang, Duffy et al. 2009).  
How amplificational replication is triggered is still unclear, but several stud-
ies have proposed an increase in E1 and E2 expression, which is regulated at the 
transcriptional level and by activation of the ATM-dependent pathway (Bedell, 
Hudson et al. 1991) (Fradet-Turcotte, Bergeron-Labrecque et al. 2011) (Moody, 
Fradet-Turcotte et al. 2007) (Mehta, Gunasekharan et al. 2015) (Sakakibara, 
Mitra et al. 2011). An increase of E2 expression has been described in the case 
of BPV-1, and an increase of mRNAs encoding E1 and E2 has been shown for 
HPV-31 (Klumpp and Laimins 1999) (Burnett, Strom et al. 1990) (Penrose and 
McBride 2000).  
The DNA damage response (DDR) pathways have been described to play an 
important role. Papillomaviruses have been shown to regulate the expression of 
certain cellular proteins as cells differentiate. In HPV-positive keratinocytes, the 
activation of caspase-3, -7 and -9 was detected upon differentiation, but activa-
tion of these in HPV-negative cells was not monitored (Moody, Fradet-Turcotte 
et al. 2007). Caspase inhibitors hampered viral amplificational replication, 
indicating that HPV-activated caspases play an important role in the vegetative 
replication phase. Caspase cleavage has been shown to be mediated by CHK2, 
which was previously activated by E7 oncoprotein binding to the ATM kinase 
(Moody and Laimins 2009). Another independent pathway of the ATM DNA 
damage response includes the cohesin protein SMC1. HPV-infected cells have 
been shown to phosphorylate SMC1 upon differentiation. This activation of 
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SMC1 and related factors results in the recruitment of this complex to the viral 
genome through binding of the insulator transcription factor CTCF to its re-
spective binding sites on the viral genome, thereby facilitating viral genome 
amplification (Mehta, Gunasekharan et al. 2015). 
 
 
2.7. Stable maintenance of PV DNA 
Viruses have evolved different approaches and mechanisms to support their life 
cycle and confirm their transmission into the progeny of infected cells. Some 
viruses, like retroviruses, convert their genomic information from RNA into 
DNA and integrate it into the host cell genome, becoming an integral part of the 
infected cells DNA. Therefore, they express, replicate and maintain their DNA 
as part of the chromosomal DNA. In contrast, all viruses that maintain their 
genomes as an extrachromosomal genetic element must have developed specific 
mechanism(s) to persist in the cell as it divides – first, the viral DNA has to 
replicate and second, it has to segregate nearly equally into daughter cells. Cur-
rently, most of the information we know about papillomavirus maintenance and 
segregation has been derived from studies of BPV-1. A cis-element, named the 
minichromosome maintenance element (MME), and E2 protein have been 
shown to be necessary for these functions. The MME is defined as a minimum 
of 6 E2BS out of 12 located in the LCR that tethers the viral genome to chro-
matin and ensures efficient segregation and maintenance of the corresponding 
plasmid in the dividing cell population (Piirsoo, Ustav et al. 1996). The studies 
of segregation mechanisms have revealed that E2 binds its C-terminal DBD to 
the viral genome, and the N-terminal TAD forms complexes with cellular teth-
ering proteins that load and keep the E2/DNA complex at the mitotic chromatin. 
As the cell divides, relatively equal copies of the viral genome are distributed to 
the daughter cell as seen from the scheme in Fig. 7. 
Although BPV-1 and HPVs are structurally very similar, and many studies 
can be extrapolated into the context of HPVs, there are significant differences 
between the segregation elements of BPV-1 and their counterparts in HPVs. 
The major difference comes from the number of E2BS that is required for viral 
genome segregation. First, the alpha-genus papillomaviruses have only 4 of 
E2BSs located in the LCR. This is significantly less than the 12 BS of BPV-1 or 
the 6 E2BS defined as MME for BPV-1. Second, several mutational analyses of 
BPV-1 have shown that the N-terminal transcription activation domain of E2, 
which is bound to many components of cellular transcription machinery, is 
required for guiding viral DNA to the transcriptionally active chromatin and for 
attachment to the mitotic chromatin (Silla, Mannik et al. 2010) (Ilves, Kivi et al. 
1999) (Abroi, Ilves et al. 2004). In accordance with this, the N-terminally trun-
cated forms of E2 – E2C and E8/E2 repressor proteins – do not interact with the 
mitotic chromatin for foci formation (Skiadopoulos and McBride 1998). How-
ever, the alpha genus HPV E2 has been shown to act as a transcriptional re-
pressor rather than having activator properties; thus, its cellular interaction part-
31 
 
ners may be different from partners of BPV-1 E2. Thus, the segregation com-
petent complex, formed in the case of HPVs, may also be different and com-




Figure 7. Schematic representation of the current model of PV segregation. E2 binds 
with the C-terminal DBD to the viral genome, and the N-terminal TAD forms com-
plexes with cellular tethering proteins that load and keep the E2 / viral DNA complex at 
the mitotic chromatin. As the cell divides, relatively equal copies of the viral genome 
are divided to the daughter cell. 
 
 
E2 does not bind directly to the DNA of the mitotic chromatin, but tethering is 
mediated through interacting with cellular proteins of the chromatin. One of the 
best described cellular interaction partners in the viral genome tethering process 
is the bromodomain family protein Brd4 (You, Croyle et al. 2004), which is 
also the first and most pronounced protein to have been described for the E2 
interaction with mitotic chromatin. Studies have shown that blocking the inter-
action of Brd4 with E2 by overexpression of the C-terminal domain of Brd4 or 
by expression of inhibiting peptides results in the loss of E2 attachment to the 
mitotic chromatin. The E2 interaction with Brd4 has been shown to be crucial 
for the attachment to chromatin for BPV-1, HPV-16 and HPV-31 (McBride and 
Jang 2013) (Wang, Helfer et al. 2013). From the other side, the universal 
requirement of Brd4 for chromatin attachment is not completely clear, as not all 
PV subtype E2 proteins interact with Brd4. In addition, the data obtained for 
Brd4 binding with E2 in the case of HPV-16 are derived from cell lines that do 
not support the transient or the stable replication of the viral genome. Addition-
ally, downregulating Brd4 with siRNA does not affect the binding of BPV-1 E2 
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and HPV-11 E2 to mitotic chromatin (Parish, Bean et al. 2006). To conclude, 
Brd4 definitely plays a role in the viral life cycle and also in the segregation of 
some papillomavirus genomes, but it does not seem to be the only receptor for 
E2 attachment to the mitotic chromatin in the process of viral genome segregation.  
Another cellular protein that interacts with E2 and seems to play a role in 
viral DNA maintenance in dividing cells is the cellular helicase ChlR1. The 
point mutation W130R, described for BPV-1 E2, failed to associate with ChlR1. 
Although transient viral DNA replication has not been hampered by this muta-
tion, the viral genomes are not maintained stably in the host cells. At the same 
time, the W130R mutation does not affect the binding of Brd4 nor the tran-
scription modulated by it. Downregulation of ChlRI with siRNA disrupted E2 
binding to the mitotic chromosomes. At the same time, the downregulation of 
Brd4 did not affect E2 binding with the mitotic chromosomes. Interestingly, 
ChlR1 is co-localized with E2 and the viral genomes in the S-phase but not in 
mitosis (Feeney, Saade et al. 2011). These facts suggest that ChlR1 may be 
required for loading of E2 and the viral genome to the chromatin, but it is dis-
pensable during the segregation process to daughter cells where other cellular 
proteins interact with the E2.  
 A third cellular interaction partner that seems to be important for the stable 
maintenance of papillomaviral genomes is the topoisomerase II-binding protein 
(TopBP1). It was initially shown to act as a transcriptional and replicational 
activator of HPV genomes (Boner, Taylor et al. 2002). Then, it was shown that 
E2 and TopBP1 colocalize during late mitosis and play a role in regulating the 
association of E2 and viral genomes in the attachment to mitotic chromatin 
(Donaldson, Boner et al. 2007). It was also demonstrated that TopBP1 is re-
quired for the efficient establishment of viral replication; viral transcription of 
the E2 mutant that does not bind to TopBP1 is not affected, but it is unable to 
establish DNA replication (Donaldson, Mackintosh et al. 2012).  
In addition, the mitotic kinesin-like protein 2 (MKlp2) that is expressed only 
during mitosis (Yu, Peng et al. 2007) has been shown to interact with BPV-1 E2 
protein. MKlp2 colocalizes with E2 in mitosis, but it is very difficult is to ana-
lyze its exact role as downregulation of MKlp2 results in growth arrest in telo-
phase and subsequent cell death (Neef, Preisinger et al. 2003) (Zhu, Zhao et al. 
2005). 
In conclusion, the factors and mechanisms that ensure HPV genome segre-
gation and maintenance remain poorly understood.  
 
 
2.8. Stable maintenance and tethering of the 
extrachromosomal genomes for other DNA viruses  
In addition to papillomaviruses, there are examples of other DNA viruses that 
maintain their genomes as episomal nuclear DNA elements. In principle, they 
use similar mitotic chromatin tethering-based mechanisms to maintain their 
genomes in dividing cells. They also recruit cellular partners to participate in 
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DNA replication and in tethering the viral genome to the chromosome upon cell 
division. Most information has been collected for Epstein-Barr virus (EBV), a 
human gamma-herpesvirus that infects a large population of humans but re-
mains largely asymptomatic. This virus infects B-lymphocytes, and the 165 kb 
circular genome is generated upon entering the cell nucleus to complete the 
viral life cycle (Deng, Wang et al. 2012). EBV has been described to possess 
four different latency types (Rowe, Rowe et al. 1987) (Babcock, Hochberg et al. 
2000), with stable maintenance and tethering of the extrachromosomal genome 
without production of viral progeny (Thorley-Lawson 2005).  
EBV nuclear antigen 1 (EBNA1) is the major viral protein responsible for 
viral transcription, replication and maintenance by binding to the viral latent 
replication origin OriP (Wu, Kapoor et al. 2002). As with E2, the EBNA1 has 
N-terminal TA and C-terminal DBD domains. The N-terminal domain contains 
sequences responsible for replication, transcription and partitioning. Interest-
ingly, the EBNA1 DBD has remarkable structural similarities with papilloma-
virus E2 DBD (Bochkarev, Barwell et al. 1995). The OriP that the EBNA1 
binds is composed of two components – the dyad symmetry element (DS) and 
the family of repeats (FR) (Reisman, Yates et al. 1985). The FR element con-
sists of 20 copies of a 30 bp sequence that also contains the 18 bp palindromic 
EBNA1 binding site (Rawlins, Milman et al. 1985). The FR region has been 
shown as the only necessary cis-element responsible for viral segregation to 
daughter cells, as the DS element contains the origin of replication activity 
(Gahn and Schildkraut 1989). On the other hand, EBNA1 has been demon-
strated as the only viral protein needed for genome segregation function, medi-
ated only through EBNA1 and FR (Sears, Kolman et al. 2003) (Nanbo, Sugden 
et al. 2007). This is in accordance with findings that, during type I latency in 
proliferating B-cells, only nuclear antigen (EBNA1) and non-coding RNA ex-
pression from the EBV genome can be observed (Thorley-Lawson 2005). 
 EBNA1 and viral DNA is not restricted to certain regions on the host mi-
totic chromosomes but rather is distributed randomly, and the FR element has 
been found to direct the viral genome to chromatin regions that are modulated 
by histone modifications and therefore also transcriptionally active (Harris, 
Young et al. 1985) (Deutsch, Ott et al. 2010). Recently, the AT-hook DNA 
binding ability of EBNA-1 has also been shown to be required for the mainte-
nance of viral genomes (Chakravorty and Sugden 2015). Additionally, a cellular 
partner EBP2 has been described to be important for the attachment of EBNA1 
to mitotic chromatin and efficient segregation (Shire, Ceccarelli et al. 1999) 
(Wu, Ceccarelli et al. 2000). The depletion of EBP2 resulted in loss of the 
segregation function (Kapoor, Lavoie et al. 2005), but EBP2 is probably not the 
only partner in the segregation, as it is only associated with telophase during 
mitosis (Nayyar, Shire et al. 2009). This indicates that the initial contact with 
chromosomes is probably mediated by an alternative partner and mechanism. 
Another well-known example is Kaposi’s sarcoma associated human her-
pesvirus type 8, which is a gamma-herpesvirus that was first identified from an 
AIDS patient with Kaposi’s sarcoma (KS) (Chang, Cesarman et al. 1994).  
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Following primary infection of the host cell, latency is established. Viral latent 
infection involves silencing of viral lytic gene expression and the stable mainte-
nance and segregation of viral episomes to daughter cells. 
The KSHV genome is composed of a 140 kb unique region that is flanked by 
an 803 bp long region containing the terminal repeat (TR) regions (Russo, 
Bohenzky et al. 1996). The circularization process of the KSHV DNA in the 
host cell nucleus is necessary to form an intact episomal maintenance element, 
which consists of tandem copies of the TR sequence (Ballestas, Chatis et al. 
1999). The KSHV encodes six viral genes by using only 11 kb of its whole 
genome for transcription (Laurent, Meggetto et al. 2008). The main viral protein 
for the segregation and stable maintenance is LANA1 – an orthologue of 
EBNA1 of EBV. Binding to the viral genome and having chromatin binding 
activity, LANA1 mediates segregation of the KSHV genome during latency. 
LANA1 is a large 222–234 kDa nuclear protein that interacts with various viral 
and cellular proteins and also dysregulates cellular pathways (Verma, Lan et al. 
2007). LANA1 asymmetrically binds to its binding sites in the TR DNA in 
contrast with EBNA-1. Recent crystal structure studies of the C-terminal do-
main of LANA1 have shown that there are at least three LANA1 binding sites 
(LBS) in the TR (Hellert, Weidner-Glunde et al. 2015). The maintenance of 
Kaposi’s sarcoma-associated herpesvirus (KSHV) episomal genome relies on 
LANA and the TR located on the viral genome (Ballestas, Chatis et al. 1999) 
(Ballestas and Kaye 2001) (Cotter, Subramanian et al. 2001). It has been shown 
that approximately 16 copies of the TR sequence are required for efficient par-
titioning of the viral genome, and two 71 bp minimal replication elements sepa-
rated by 801 bp center-to-center spacing are required for efficient stable repli-
cative maintenance (Shrestha and Sugden 2014). For the efficient establishment 
and maintenance of viral genomes, LANA1 is responsible for viral DNA repli-
cation interacting by the C-terminal DBD with two sites in the TR (Garber, Hu 
et al. 2002). A number of cellular proteins has been described to act as potential 
partners for KSHV genome segregation (reviewed in (Feeney and Parish 2009), 
but perhaps the most interesting target would be LANA docking with the nucle-
osomes. LANA uses its N-terminal domain to dock with nucleosomes through 
binding with histones H2A-H2B and might use this attachment to nucleosomes 
to persist during cell division (Barbera, Chodaparambil et al. 2006). Addition-
ally, similarly to papillomavirus E2 proteins, LANA1 interacts with the bromo-
domain family proteins Brd2 and Brd4 to colocalize on mitotic chromatin (You, 
Srinivasan et al. 2006) (Viejo-Borbolla, Ottinger et al. 2005). As with the 
studies of papillomaviruses, the exact mechanisms of the tethering process are 
still unknown, and current data indicate that the process could involve several 
cellular partners that are participating and active in different stages of the cell 




3. MATERIALS AND METHODS 
One of the pillars of this thesis is the development of a new cellular system that 
would allow efficient study of various characteristics of the viral life cycle 
using molecular biology techniques. The U2OS cells described herein are a cell 
line capable of replicating various HPV genotypes, and we demonstrate the 
relevancy of the cell system in depth regarding DNA replication and the tran-
scriptional map of HPV-18 replicating in U2OS cells (Ref I & II). For propaga-
tion of HPV genomes, these were cloned into regular cloning vectors suitable 
for E. coli strains. However, for studies of HPV genomic DNA, the bacterial 
backbone must be removed. Instead of restricting out the backbone and trans-
fecting cells with re-ligated viral genomes, we implemented the minicircle 
attB/attP-Bxb1 recombination system to generate viral (ccc) genome molecules 
that could be used directly to transfect cells (Kay, He et al. 2010) (Wang, 
Meyers et al. 2011). 
The first transient amplification of HPV genomes was achieved by trans-
fecting U2OS cells with minicircle plasmids containing HPV genomes; the 
stable maintenance replication of HPV was obtained by generating stable HPV-
positive subclones from U2OS cell lines after selection, and the vegetative am-
plificational replication of HPV genomes was achieved by using dense cell 
culture conditions cultivating stable HPV-positive cell lines. 
In Fig. 8 I represent the general workflow approach that was used in these 
studies. Several cloning techniques have been used to generate DNA plasmids 
expressing either viral, cellular or marker proteins, including gene synthesis, 
PCR, and single nucleotide mutagenesis. Considering the design of the experi-
ments, plasmid DNA was transfected via electroporation into the cells, after 
which downstream analytical methods were performed. A detailed overview of 
the materials and methods used in this study are located in the appropriate sec-




Figure 8. Schematic representation of the general workflow of HPV-related studies 
used for this thesis. Depending on the experiment design, plasmids were transfected to 
immortalized cells, after which downstream analytical methods were performed.  
36 
 
The second methodical pillar to be highlighted is the development of the HPV-18 
segregation assay (Ref III). The principle of this assay has been published 
previously in the context of BPV-1 (Abroi, Ilves et al. 2004). The assay consists 
of a non-replicating plasmid that expresses two factors – the viral E2 protein for 
the tethering of the plasmid to mitotic chromatin and a short-lived fluorescent 
protein d1EGFP (Li, Zhao et al. 1998) expression cassette for monitoring the 
persistence of the plasmid in dividing cells using FACS. The assay plasmid also 
contains a region that allows the insertion of DNA sequences bearing the E2 
binding sites. Due to short half-life of the marker, the fluorescence indicates the 
presence and expression of the plasmid in the cell. Using FACS for the meas-
urement of GFP-expressing cell numbers over time allows us to calculate the 
relative segregation efficiency of plasmids with different combinations of cis-
elements. We have used this approach to create the assay plasmid in the context 
of HPV-18 and studied the segregation properties of HPV-18 cis-elements. As 
described in Figure 10 below, by monitoring the change of GFP-positive cells 
over time it is possible to conclude the segregation efficiency of the plasmid, 
i.e., in comparison of a plasmid lacking any segregation competent elements. In 
case of a segregation positive plasmid, we see the number of GFP positive cells 
increasing over time as the plasmids are tethered to the mitotic chromatin and 
thereby hitchhike to the daughter cell. In case we have a plasmid that is segre-
gation incompetent, we do not see an increase in numbers of the GFP-positive 
cells, and they instead show a decrease over time as the plasmids either segre-
gate randomly to daughter cells or are lost during the cell cycle. As the E2 pro-
tein is a major viral regulator, mutations of E2BS in the context of the viral 
genome or LCR-replication plasmids result in modulation of transcription and 
DNA replication. Therefore, it is difficult to make any conclusions on the spe-
cific mutation in the context of DNA segregation and partitioning. Our assay is 
advantageous in the aspect that it allows us to specifically dissect the role of E2 
in the segregation/partitioning process. Using this assay system, we proceed to 
describe the cis-elements for segregation of HPV-18 DNA in the following 




4. RESULTS AND DISCUSSION 
4.1. Objectives of the study 
Although a preventive HPV vaccine is available for several subtypes, the 
pressing issue of a large number of cervical cancer cases globally remains. 
However, people who are already infected or unable to vaccinate against HPV 
are still at risk. A limitation in the development of therapeutic solutions against 
HPV infection is caused by the lack of suitable cellular model systems that are 
capable of hosting HPV and supporting different facets of viral mechanisms – 
DNA replication, transcription and latency. These systems would allow to study 
the aspects of HPV molecular biology and use the knowledge to identify novel 
antiviral strategies. For this thesis, the establishment of such a model system has 
been described. This creates the opportunity for comprehensive studies of fun-
damental HPV properties also included herein. The objectives of the thesis are: 
a) To characterize the human U2OS cell line as a suitable host capable of 
initiating and supporting stable genomic replication of several different 
HPVs (Ref I);  
b)  To describe the HPV-18 transcription map in U2OS cells during transient 
replication, stable maintenance and vegetative amplification, including the 
definition of the promoter regions, polyadenylation sites and mRNA species 
(Ref II);  
c) To characterize the specific elements and factors required for viral genome 
segregation and stable maintenance (Ref III). 
 
 
4.2. U2OS as a suitable model system  
for HPV-related studies (Ref I) 
When Harald zur Hausen first proposed the hypothesis that cervical cancer is 
caused by papillomaviruses in 1976, these became one of the most extensively 
studied viruses. The ability of papillomaviruses to transform cells gave the field 
the cell lines HeLa and SiHa harboring integrated sequences of HPV-18 and  
-16, respectively, that have enabled the gathering of invaluable information in a 
variety of fields – virology, cancer biology, and immunology (Durst, Gissmann 
et al. 1983) (Boshart, Gissmann et al. 1984). As science and the available tools 
for research were evolving, a larger emphasis was directed onto the molecular 
biology of papillomaviruses. As animal papillomaviruses were considered 
model systems for HPV, a large portion of scientific research was performed in 
the context of the Bovine Papillomavirus Type-1 (BPV-1), after which the ini-
tial findings were mostly confirmed in the context of HPV. The fact that cellular 
systems suitable for modeling different mechanisms of BPV-1 were available 
was the main cause of its development as the main target of papillomavirus 
research. For example, studies from BPV-1 have led to major findings regarding 
the replication of papillomavirus DNA and have given many insights into how 
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cellular DNA replication occurs. These type of studies were possible due to the 
availability of the suitable cell line C127 that supported the replication and 
transformation of the BPV-1 genome (Law, Lowy et al. 1981). However, these 
cells do not support the replication of HPV. 
Papillomaviruses are species-specific viruses, and the microenvironment of 
the cell determines the functionality of the virus within the cell. The virus may not 
perform the same in different cell lines – for example, papillomaviruses replicate in 
keratinocytes but do not replicate in other cell types. The possibility of generating 
E1- and E2-expressing cell lines of BPV-1 gave useful information about the stable 
maintenance of BPV-1 DNA, determining the requirements for viral DNA 
segregation and mapping the MME (Piirsoo, Ustav et al. 1996). Transferring 
this approach into the context of HPV has failed several times for our group. Now 
we can conclude that the reason for this might be the ability of E1 to create 
double-strand-breaks (DSB) and thereby induce the DNA damage response 
pathway (DDR), resulting in either cell-death or stalled cell cycle (Sakakibara, 
Mitra et al. 2011) (Gillespie, Mehta et al. 2012) (Reinson et al. 2013). 
For more authentic studies of HPV molecular biology, we needed to find a 
robust, easily cultivable cell line that supports the genome replication and gene 
expression of LCR (ori)-containing plasmids as well as intact viral genomes. In 
the quest for a suitable cell line, our research group tested a number of cell lines 
for the ability to support replication of high- and low-risk HPV DNA. We found 
that human osteosarcoma cell line U2OS (previously named 2T) supported the 
replication of HPV DNA. The U2OS cell line is derived from a 15-year-old girl 
who had a moderately differentiated osteogenic sarcoma of the tibia (Ponten 
and Saksela 1967). U2OS cells have been characterized to have an epithelial-
like growth pattern and retain mitotic activity even when cultivated at high-
density. In comparison with primary keratinocytes, cultivation of U2OS is much 
more robust – they are easily transfectable, are cultivated in standard cell cul-
ture medium, and undergo unlimited cell divisions with an approximate dou-
bling time of 29 hours. As infection with viral particles is not a possibility, to 
mimic viral entry we transfected HPV viral genomes into U2OS cells via elec-
troporation. As seen from Ref I Fig. 1, after the transfection of 6 different epi-
somal viral genomes, the DpnI-resistant HPV-specific signals were detected for 
all HPV subtypes. As the U2OS cells enabled replication of the alpha-genus 
papillomavirus types 6, 11, 16 and 18 DNA that infect the mucosal epithelium, 
it was even more surprising that it was able to transiently and stably replicate 
the beta-genus type papillomaviruses HPV5 and HPV8 that infect cutaneous 
epithelia. A suitable cellular model system had been completely lacking for 
cutaneous HPV studies, and the fact that these genomes replicate transiently and 
are maintained in the cells provides a valuable tool for a deeper understanding 
of the characteristics of these viruses.  
To validate that the initial replication of HPV genomes were dependent on 
the presence of the papillomavirus replication proteins E1 and E2 and not due to 
an artifact generated by the cell, we constructed E1 and E2 frameshift mutants 
in the HPV-18 genome. We clearly demonstrated that mutant viruses not  
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expressing either E1 or E2 protein were unable to replicate in U2OS cells (Ref I 
Fig. 1E and scheme Fig. 3H). In contrast, when we co-transfected the mutant 
genomes with either E1 or E2 expression vectors, replication was rescued. 
Moreover, when co-transfecting the E1 and E2 mutant genomes together in a 
complementation assay, we could see the replication activity restored for both 
mutants, as E1 was provided from the E2 minus genome and E2 from the E1 
minus genome. Thus, we concluded that HPV genome replication in U2OS is 
E1- and E2-dependent.  
In addition to the transient replication, we were able to see that the replica-
tion signals persisted over time, indicating that the replicating viral genomes 
were tethered properly to the dividing daughter cells. Long-term cultivation of 
cells transfected with viral genomes under selective conditions, and even with-
out selection, revealed that the cell pools were efficiently harboring viral ge-
nomes as seen in Ref I Fig. 2A. Furthermore, subclones of single cells contain-
ing the stably maintained viral genomes were obtained for all six tested sub-
types with high efficiency (Ref I Fig. 2B). Interestingly, in addition to the tran-
sient HPV DNA replication and stable replication of HPV genomes, we were 
able to monitor induced amplificational replication. Specifically, when U2OS 
cells that maintained the HPV genome were cultivated in a confluent state, we 
were able to see a 2-6-fold increase of the viral DNA copy number (Ref I Fig. 3C). 
In some aspects, the amplification has remarkable similarity to the productive 
stage of the HPV life cycle. Studies with keratinocytes have shown that 
cultivation of cells in confluency may lead to differentiation of the cell, mean-
ing also that the microenvironment–transcriptional profile of the cell also 
changes (Poumay and Pittelkow 1995). Although the U2OS cells are trans-
formed and do not differentiate, the mechanism of transcriptional modulation of 
cellular proteins in confluency could be used to explain this phenomena. The 
relative mRNA levels of viral transcripts in HPV-transfected cells in confluency 
started to rise approximately 5 days after initiation. Interestingly, the mRNA 
levels of L1 were also observed, although no late viral proteins or viral particles 
were detected. Studies of the transcription map of HPV-18 in U2OS (Ref II, 
Fig. 2B) revealed that in the case of 1.13 subclone harboring HPV-18 viral 
genomes, the use of late polyadenylation sites was detectable, and it increased 
as cells were kept in confluent conditions. Similar results were observed in case 
of the HPV-11 transcriptome map, in which case the late polyadenylation site 
was more active during cell confluency (Isok-Paas, Mannik et al. 2015). 
The surprising finding of the U2OS system was the physical state of the viral 
genomes. As papillomaviruses are known to be 8 kb dsDNA molecules, they 
are expected to replicate and remain as such in the cell. However, in addition to 
the monomeric 8 kb molecules, we were able to detect a large prevalence of 
oligomeric forms of HPV DNA (Ref I Fig. 5A and 5B). In case of the HPV-18 
clone #1.13 that harbors the episomal genome, it was evident that the majority 
of the viral genome was in an oligomeric state. Such oligomeric forms of HPV 
have previously been described from tissue samples taken from patients 
infected with HPV, and they were also detected in patient biopsy samples  
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obtained in this study (Boshart, Gissmann et al. 1984; Durst, Kleinheinz et al. 
1985; Cullen, Reid et al. 1991). The exact mechanism and cause of the for-
mation of such oligomeric HPV DNA molecules has remained unknown, but as 
viral genomes are capsulated in the viral capsid as monomeric molecules,  
a mechanism to revert this process has to be included in the process. One 
hypothesis of why the virus maintains its genome as an oligomeric DNA 
molecule could be explained by superior stable maintenance of the viral genome 
and efficient segregation to the daughter cell. As has been described for BPV-1, 
a minimum of 6 E2 binding sites are required for the genome to segregate effi-
ciently to daughter cells. In the case of alpha-genus papillomaviruses, there are 
only 4 E2BS located in the viral genome. As the viral genome is in a oligomeric 
form, the number of E2BS and therefore potential “anchorpoints” per molecule 
are also increased, resulting in more efficient segregation and partitioning to 
daughter cells.  
In the light of the data obtained from this study, we were able to conclude 
that HPV genome DNA efficiently replicates in U2OS cells, and replication 
initiation is E1- and E2-dependent. U2OS cells support the replication of both 
cutaneous and mucosal skin infecting HPVs; low- and high-risk genotypes and 
the U2OS system are able to mimic all three phases of viral replication – initial 
amplificational replication, stable replication and even vegetative-like replica-
tion upon confluency of the cells. This enables U2OS cells to become a tool for 
replication and viral genome stable maintenance-related studies, and we will 
target these approaches further in our studies.  
 
 
4.3. Characterization of the transcription map of  
HPV-18 in U2OS and two E2C mRNA species (Ref II) 
To confirm the relevancy of the U2OS system for HPV studies beyond E1- and 
E2-dependent replication, we needed to describe the characteristics of the virus in 
the cell in more detail. Thus, we aimed to study and characterize the transcription 
map of the HPV-18 genome replicating in U2OS cells. At the time, a study had 
just been published about the trancriptional map of HPV-18 during productive 
infection in raft cultures that had been established as a renowned system for HPV-
related studies and could be used as a reference (Wang, Meyers et al. 2011).  
It was evident that the transcription maps in Wang et al. and in U2OS cells 
were very similar in aspects of promoter regions, early PAS usage as well as 
splicing patterns and mRNA species (Fig. 9). We defined 5 promoter regions in 
HPV-18 genomes replicating in U2OS cells: P102, P520, P811, P1193 and a 
less pronounced P3000 (Fig. 9 below). Similar to the observations from raft 
cultures, the P102 promoter was most actively used for the expression of early 
viral transcripts, and it had previously been described in cervical carcinoma cell 
lines, primary human keratinocytes transfected with HPV genomes and in  
HPV-18-infected raft cultures (Romanczuk, Thierry et al. 1990) (Schneider-
Gadicke and Schwarz 1986; Thierry, Heard et al. 1987; Wang, Meyers et al. 
41 
 
2011). The transcripts initiated from P102 have the potential to encode all viral 
early proteins, with exception of E8^E2C (Ref II. Fig. 6). P520 is located in the 
E6 ORF and has not been previously defined as a viral promoter, although 
spliced transcripts initiated from this region have been previously demonstrated 
in HPV-18 in raft culture (Wang, Meyers et al. 2011). P811 has been described 
as the late promoter that is activated as cells enter differentiation. In the case of 
the U2OS system, activation was detected when cells were kept in confluency. 
The P1193 promoter is also poorly described but is also detected in the raft 
culture system that has been used as a reference. The initiation of transcription 
from the region mapped to the P3000 promoter has been published before in in 
vitro transcription studies and in HeLa cells (Karlen and Beard 1993), but the 
function of these transcripts has not been analyzed in previous studies. 
Our analysis revealed two transcripts that had the potential to encode 
truncated forms of E2, containing sequences of the E2C domain. One spliced 
transcript encoded an E2C-1 protein that contains a peptide encoded by nt 
3253–3255 nt in E2 ORF that is then fused to the C-terminal domain of E2 by 
splicing (Fig. 9, transcript I). The second unspliced mRNA could encode a 
putative E2C-2 protein that initiated from internal ATG in E2 ORF nt 3426)  
(Fig. 9, transcript U) .  
A similar E2 ORF that initiated expression of truncated E2 variants contain-
ing only the C-terminal part of E2 has been described for BPV-1 and HPV-11 
(Liu, Kuo et al. 1995) (Lambert, Spalholz et al. 1987; Choe, Vaillancourt et al. 
1989) (Lambert, Hubbert et al. 1989; Vaillancourt, Nottoli et al. 1990). These 
truncated E2 proteins can modulate full-length E2 activities by competing with 
E2-binding sites in the genome or by forming heterodimers with it. Thus, E2C-1 
and E2C-2 are similar to most studied regulator E8‘E2 protein, consisting of a 
short E8 product (11 amino acids) that is fused to the C-terminal part of the E2 
protein. We also analyzed 302 PVs from the PaVE database and found that 
methionine can be used for translation initiation of E2C-2 and is conserved in 
all a7 family HPVs (types 18, 39, 45, 59, 68, 70, 85 and 97) as well as in HPV-67 
(a9 family). 
Due to the lack of available sensitive immunological reagents, we could not 
analyze the expression of these proteins from the HPV-18 genome. Instead, to 
analyze the role of E2 DBD-containing proteins in the context of viral genome 
replication and copy number control, we mutated the ATG codons in E8, E2C-1 
and E2C-2 alone and in combinations. We analyzed the transient replication of 
these mutant genomes (Ref II Fig. 7A) by Southern blot. In accordance with 
previously published data, mutation of the E8 protein resulted in an approxi-
mately 10-fold increase in replication activity (Kurg, Uusen et al. 2010). In the 
case of the E2C-1 mutation, we did not observe any significant effect on repli-
cation, but E2C-2-mutated viral genomes replicated with near 2-fold lower 
efficiency. The results indicate that E8^E2C represents a major repressor of HPV-
18, and copy number control can be achieved mostly by this protein, at least in 
transient replication. It does not exclude a role for E2C1 and E2C2 in other 




Figure 9. Schematic overview of HPV-18 transcripts mapped in U2OS cells by 5’ 
RACE along with marked promoter regions and cleavage site locations (top).  
 
 
Thus, we also analyzed the effects of the E2C proteins as transcriptional modul-
ators of the viral promoters. Conducting RACE assays of wildtype vs. mutated 
genomes revealed that E2C-2 could moderately de-activate the main viral 
promoter P102, which could explain the weaker replication of this mutant (Ref II 
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Fig. 8 E–F). Thus, the reduction of transient replication activity by the E2C-2 
mutation may be explained by transcriptional repression function of this protein.  
Our group has also performed the transcriptome map of cutaneous HPV-5 
and low-risk mucosal HPV-11 genomes that actively replicate in U2OS cells 
(Sankovski, Mannik et al. 2014; Isok-Paas, Mannik et al. 2015). Beta-papil-
lomavirus replication and transcription studies have remained in the background 
of other cancerogenic forms of HPV, but this has also largely been due to the 
lack of suitable cellular model systems. It was demonstrated that HPV-5 
replicating in U2OS cells is also E1- and E2-dependent, and 4 early promoter 
regions were described with a total of 14 different viral mRNA species origi-
nating from the viral genome. Additionally, the E8^E2C transcript was detected 
for HPV-5, with similar repressor functions of viral genome replication as other 
HPV types. The HPV-11 transcriptome map confirmed previous results ob-
tained with HPV-related lesions and additionally confirmed that viral replica-
tion and transcription in U2OS truly reflects the effects seen in nature. 
 In summary, the results of this study strongly suggest that the transcriptome 
map of HPV-18 (and a separate study published on HPV-11 and HPV-5 repli-
cating in U2OS cells) describe the natural status of the viral genome and 
thereby further emphasize that the U2OS cells are a relevant system for HPV 
replication- and transcription-related studies.  
 
 
4.4. Viral cis-elements required for  
HPV-18 stable maintenance (Ref III) 
Papillomaviruses infect basal epithelial cells and, in order for them to be main-
tained in dividing cells, they need to hitchhike to the daughter cells. For the 
stable maintenance of latent infection of papillomaviruses and herpesviruses 
(EBV and KSHV) in dividing host cells, there are two requirements that the 
virus must fulfill. First, it must replicate its DNA, and secondly, it must segre-
gate its genome equally to daughter cells.  
These functions are mediated by E1 and E2 proteins in papillomaviruses 
(Piirsoo, Ustav et al. 1996), but in the case of herpesviruses, they are mediated 
by EBNA1 for EBV (Lee, Diamond et al. 1999) and LANA1 for KSHV 
(Ballestas, Chatis et al. 1999). The binding sites of the chromatin binding viral 
factors located on the viral genome are crucial anchorpoints for efficient teth-
ering of the viral genomes to the host mitotic chromosome. The latter is used as 
a vehicle for the safe and loss-less segregation of the viral DNA into the newly 
forming nuclei of daughter cells (Fig. 7). 
As previously described, a large portion of our knowledge of different as-
pects of the papillomavirus life cycle was initially generated from studies of 
BPV-1. This is also true for the viral factors and elements for genome segrega-
tion and maintenance. Mapping of the minimal cis-elements required for BPV-1 
stable replication and maintenance was possible because of an E1/E2-express-
ing cell line. In BPV-1, it has been shown that the E2 protein and 6 E2BS  
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enable efficient partitioning of viral DNA to daughter cells (Ilves, Kivi et al. 
1999) (Abroi, Ilves et al. 2004). The E2 protein is the only viral protein 
demonstrated to be required for attachment to mitotic chromatin. Attempts to 
put these approaches in the context of HPV have been problematic due to 
several aspects that have now become obvious – for example, HPV E1 acting as 
an activator of the DDR pathway and thereby limiting the possibility of 
obtaining E1/E2-expressing cell lines and also due to reasons currently 
unknown (Sakakibara, Mitra et al. 2011).  
Due to these difficulties, a different approach had to be developed to study 
these mechanisms in HPV. Abroi et. al published a study describing a d1-EGFP 
marker-based segregation assay in a Jurkat suspension cell line that allows 
monitoring of non-replicating plasmid maintenance in dividing cells (Abroi, 
Ilves et al. 2004) (see Materials and Methods section). Such an assay system has 
provided information on the minimal segregation elements of BPV-1, and ala-
nine scanning mutations of E2 have provided information on positions crucial 
for the efficient segregation complex formation. We used the same approach to 




Figure 10. Cartoon representing the division of GFP cells transfected with segregation 
competent plasmids and segregation incompetent plasmids.  
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All alpha-genus papillomaviruses have 4 E2BS in their LCR, and we con-
structed a number of different combinations of HPV-18 E2BS-containing seg-
regation plasmids (Ref III Fig. 2B). As the total number of E2BS in the LCR of 
HPV-18 (4) is fewer than the minimal number of E2BS needed for the segrega-
tion of BPV-1 (6), we hypothesized that several cellular proteins and their re-
spective binding sites in LCR might contribute to the segregation of viral DNA. 
However, as seen in Ref III Fig. 2C, this hypothesis was not true, as HPV-18 
segregation plasmids containing only the plain 4 E2BS and not any other 
sequence from the LCR were segregating with same efficiency as the full length 
LCR containing plasmid. In conclusion, we found that 2 E2BS were the mini-
mal cis-elements providing plasmid segregation in our assay. 
It became evident that the 4bp CGGG linker between the E2BS1 and E2BS2 
in LCR seemed to be crucial for the partitioning function. As we created linker 
modifications by doubling, tripling or deleting the 4 bp linker (Fig. 11.A 
below), we saw that increasing the spacing between E2BSs enhanced the effi-
ciency of segregation, even exceeding the plasmids that contained the full LCR 
region (Fig. 11.B below). As we know that the DNA helix requires 10 bp for a 
full turn (Wang 1979), and E2 bind its respective binding sites cooperatively 
(Monini, Grossman et al. 1991), we were contemplating that perhaps by chang-
ing the spacing between the two E2BS we also sterically enhanced the proper-
ties of E2 binding by cooperative binding. Cooperative binding has been shown 
to occur with many cellular proteins and transcription factors and has been pro-
posed as a reason for synergistic effects during transcription, as the binding of 
one protein to its ligand improves the affinity of the other protein molecule 
towards its ligand (Kazemian, Pham et al. 2013). The electrophoretic mobility 
shift assay (EMSA) confirmed our hypothesis, and we were able to see a 5-fold 
increase in the cooperative binding of E2 in the case of the doubled linker and a 
3-fold increase in the case of the tripled linker (Fig. 11.D below). The plasmid 
that lacked the linker completely was unable to bind two E2 dimers, and only 1 
E2BS could be occupied, likely due to steric interference of the already bound 
E2 dimer (Fig. 11.C below). These data demonstrated a correlation between the 
positioning of the E2 binding sites and the cooperative binding of two E2 




Fig. 11 (A) Schematic representation of the E2BS 1&2 linker mutations (B) Segregation 
assay with the 0-, WT-, 2- and 3-linker segregation plasmids. (C) Electrophoretic mo-
bility shift assay (EMSA) performed with purified E2 protein and E2BS (Scheme A) as 
the probe. 0-linker probe was able to bind only one E2 dimer and formed a single 
DNA:protein complex. (D) Quantitated results of the EMSA and calculated cooperative 
binding factors.   
 
Next, we used a U2OS-based system to test the effects of implementing these 
E2BS 1&2 linker mutants in the context of the LCR or intact viral genomic 
DNA. We tested the ability of these mutant genomes to replicate transiently and 
even more importantly to maintain the viral genome and see if it confirmed the 
data obtained from the segregation assay (Ref III Fig. 5). We tested the effect of 
linkers by transient replication of a HPV-18 LCR-containing plasmid (HPV-18-
URR), initiated by co-transfection of E1 and E2 expression vectors. This pure 
replication assay allowed us to exclude any effects of transcriptional modulation 
due to the linker mutations laying near the viral main promoter P102. In this 
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assay, the longer linker did not affect the replication ability, but the 0-linker 
URR plasmid replicated with a near 3-fold decreased efficiency. Testing the 
same mutations in the context of the full-length viral genome transient replica-
tion, the same 0-linker HPV-18 genome replicated with approximately 5-fold 
increased efficiency, and increased replication efficiencies were observed with 
increased E2BS linker mutants (Ref III Fig. 5.B). We were also able to see that, 
although the 0-linker genome was replicating more efficiently in the transient 
mode then in stable replication, the mutant genome was not maintained prop-
erly, correlating with the results obtained previously in the segregation assay, 
whereby the 0-linker plasmid was unable to segregate properly to daughter 
cells. 
We attempted a complementation assay by adding extra E2BS combinations 
into the late region of the 0-linker mutant to test if the rescue of stable replica-
tion could be obtained by the addition of a functional E2BS pair (Ref III  
Fig. 5.D). Unfortunately, the addition of E2 binding sites abolished the viral 
transient replication for unknown reasons. This might have been due to destabil-
izing the mRNA of viral transcripts, as deletion of the late region itself did not 
affect the ability of such “early” genomes to replicate (Geimanen, Isok-Paas et 
al. 2011). Collectively, the data suggested that the natural positioning of E2BS1 
and 2 are crucial for stable replication and segregation of the viral genome. 
The possible mechanisms leading to increased transient replication of  
0-linker mutation-bearing genomes came from further transcription analyses. 
Precisely, we performed a 5’ RACE assay to detect the early viral mRNAs, 
similar to Ref II above, and an RT-PCR assay for quantitation of specific 
mRNAs compared with WT HPV-18. We demonstrated decreased P102 pro-
moter activity together with increased levels of transcripts arising from P1193 
for the 0-linker HPV-18 genome. By sequencing the transcripts arising from 
P1193 transcripts, we were able to detect that the majority of represented 
mRNAs had the potential to express the E8^E2C repressor protein (Ref III  
Fig. 6B). There was an increase in E2 transcripts for all mutant genomes, which 
might also explain the improved transient replication efficiency (Ref III  
Fig. 6C). Thus, it seems that the effects of the linker mutants result in changes 
in the optimal balance of the viral transcripts, including those encoding viral 
replication factors and repressor proteins, and the natural architecture of the 
E2BSs has been evolutionarily established as optimal for the regulation of the 
HPV-18 life-cycle.  
The fact that E8^E2C mRNA levels are increased but repressor functions are 
not detectable indicates that either E8^E2C is not able to bind to the single 
available site or binding to only one E2BS is not sufficient for the repressive 
function, and E8^E2C repression cannot be mediated by E2BS 3&4. Our results 
are in agreement with epigenetic studies that have shown that the downstream 
E2BS 1&2 in the LCR are mediating transcriptional repression, and E2BS 3&4 
are required for transcriptional activation (Johannsen and Lambert 2013) 
(Chaiwongkot, Vinokurova et al. 2013). The E8^E2C inhibited repressor effect 
also gives ground to the assumption that the 0-linker genome improved 
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replication ability is due to the activation of E1 and E2 that help to lift the repli-
cation level similar to WT-HPV-18 genomes, although the 0-linker is comprised 
of efficient replication initiation. The role of E8^E2C in stable maintenance of 
viral genomes is somewhat controversial. Although the repressive function of 
E8^E2C seems to be conserved throughout different papillomaviruses, a study 
has shown that E8^E2C is required for efficient maintenance of viral genomes 
in HPV-31, but in HPV-16, it has been shown to be dispensable for persistence 
(Stubenrauch, Hummel et al. 2000) (Lace, Anson et al. 2008). Studies in our 
group with E8^E2C mutants have indicated that a drop of copy number occurs 
during stable replication, but viral genomes are not completely lost (Kurg, 
Uusen et al. 2010). Either the loss of viral genomes in the case of the 0-linker 
genome is due to E8^E2C, or E2’s inability to bind to E2BS 1&2 is unclear and 
requires further investigation. However, it is clear that E2BS 1&2 represent a 
crucial cis-element for segregation, and binding of E2 proteins to these sites is 







We have identified a human osteosarcoma cell line U2OS that is able to support 
replication and maintenance of different HPV genomes. We have described this 
cellular model system in detail and used it to provide new insights into various 
aspects of HPV-18 molecular biology. The main results of this thesis have been 
previously published in international peer-reviewed journals and generated two 
patents. In summary, we have:  
• Described the development of a cellular assay system enabling the study of 
the transient, stable, and amplificational replication of both high- and low-
risk HPV genomes; 
• Provided a complete overview of the transcriptome map of HPV-18 as it 
replicates in U2OS cells and showed its similarity to transcription described 
in productive infection in KCs; 
• Characterized viral cis-elements that are crucial for HPV-18 segregation and 
latency and described the importance of E2BS architecture in viral LCR for 
effective E2 binding and concerted regulation of the viral life cycle.  
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SUMMARY IN ESTONIAN 
HPV-18 genoomi jagunemine ja säilumine rakkudes 
Papilloomiviirused on väikesed ligikaudu 8000 aluspaari pikkuse kaheahelalise 
DNA genoomiga viirused, mis nakatavad spetsiifiliselt keratinotsüüte naha ja 
limaskesta epiteelkoes. Papilloomiviiruste roll emakakaelavähi tekkes hakkas 
lahti hargnema 1970ndatel aastatel, kui Prof. Harald zur Hausen esimest korda 
tuli välja hüpoteesiga, et emakakaelavähi põhjustajaks võivad olla just need 
viirused. Tõepoolest on praktiliselt kõikides kliinilistes emakakaelavähi proo-
vides võimalik tuvastada papilloomiviiruse DNA ning juba 1980ndatel aastatel 
eraldati esimesed inimese papilloomiviiruste (HPV-de) genoomid. Sellest alates 
muutus HPV uurimine ülimalt intensiivseks ning järjest arenevaid molekulaar-
bioloogilisi meetodeid kasutati ka papilloomiviiruste molekulaarsete mehha-
nismide – replikatsiooni, geeniekspressiooni ja vähi tekke - uurimiseks.  
Kliiniliselt jaotatakse papilloomiviirused kõrge- ja madala riskiga papil-
loomiviirusteks, sõltuvalt nende võimest tekitada pahaloomulisi kasvajaid. 
HPV-16 ja HPV-18 on kirjeldatud kui kõige levinumad kõrge riskiga papil-
loomiviiruse tüübid, mis põhjustavad ligi 90% kogu emakakaelavähi juhtudest. 
2006. aastal tulid turule esimesed vähivastased vaktsiinid – preventatiivsed vak-
siinid nelja enimlevinud papilloomiviiruse vastu. Paraku pole need vaktsiinid 
veel jõudnud laialdaselt levida riiklikesse vaktsineerimisprogrammidesse ning 
miljonid juba nakatunud ja nakatuvad inimesed on siiski ohus. Juba välja kuju-
nenud nakkuse puhuks antud hetkel spetsiifilisi viirusvastaseid ravimeid pole 
ning nende ravimite leidmisel on olnud oluliseks takistuseks sobiva rakulise 
uurimisplatvormi olemasolu, mis aitaks efektiivselt kaasa viiruse elutsükli eri-
nevate tahkude uurimisele molekulaarsel tasandil.  
Käesolevas töös kirjeldame inimese osteosarkoomi rakuliini U2OS kasu-
tamist inimese papilloomiviiruse molekulaarbioloogia uurimise platvormina. 
Me avastasime, et sellel rakuliinil on haruldane omadus toetada nii naha, kui ka 
limaskesta rakke nakatavate HPV subtüüpide genoomi replitsiooni. Lisaks esi-
algset nakkust mimikeerivale amplifikatsioonilisele replikatsioonile olid viiruse 
genoomid võimelised jagunevates rakkudes ka säiluma, mis viitas asjaolule, et 
viiruse genoom jaotatakse ühtlaselt tütarrakkude vahel. Seega on seda süsteemi 
võimalik kasutada ka latentse viirusnakkusega seotud küsimuste uurimiseks. 
Kui organismis kulgeval nakkusel viirusega nakatunud rakk lahkub naha basaal-
membraanilt, differentseerub ning hakkab epiteelkoe kihis liikuma naha välis-
osale, toimuvad rakkude sisekeskkonnas muutused ning koostöös viirusvalku-
dega käivitub viiruse genoomi teistkordne paljunamine ning kapsiidivalkude 
ekspressioon, et valmistada ette piisavalt viiruse genoomi koopiad, mis oma-
korda pakkuksid viiruse kapsiidi. Huvitaval kombel on võimalik ka antud 
replikatsioonifaasi teatud määral mimikeerida U2OS rakkudes, kus sobivate 
keskkonnatingimuste puhul ilmneb kapsiidivalkude geenide promootori ja polü-




Käesoleva tööga seotud järgnevas publikatsioonis me näitasime täiendavalt 
U2OS süsteemi autentsust viiruse uurimiseks. Kui senini olime me kesken-
dunud genoomi replikatsioonile, siis nüüd koostasime HPV-18 transkriptoomi-
kaardi U2OS rakkudes. Meie tulemustest ilmnes selgelt, et antud transkript-
sioonikaart oli väga sarnane tulemustega, mis samu meetodeid kasutades saadi 
HPV18 produktiivse nakkuse korral primaarsetes keratinotsüütides. See kin-
nitab meie poolt avastatud U2OS-põhise süsteemi relevatsust papilloomiviiru-
sega seotud uurimustöödeks. Lisaks kirjeldasime kaht uut repressorvalku, mida 
HPV-18 ekspresseerib ning millel näib olevat roll viiruse geeniekspressiooni ja 
replikatsiooni modulleerimisel.  
Käesoleva töö kolmandaks tahuks on olnud mehhanismide kirjeldamine, mis 
on vajalik viiruse genoomi säilumiseks jagunevates rakkudes. Selle valdkonna 
muudab eriti oluliseks asjaolu, et papilloomiviiruse pikajaline latentne säilimine 
on üks potentsiaalsetest märklaudadest viirusvastaste ravimite väljatöötamiseks. 
Valdav enamus teadmistest selle funktsiooni kohta on seni pärinenud veise 
papilloomiviiruse tüüp-1 (BPV-1) alastest uurimustöödest, mis määratlesid 
viirusvalgud E1 ja E2 ja piisava arvu E2 valgu seondumiskohti genoomis kui 
vajalikud latentseks replikatsiooniks jagunevates rakkudes. Samas polnud neid 
teadmisi võimalik üle kanda inimese papilloomiviirustele, kuna E2 seondumis-
kohtade arhitektuur viiruse genoomil on HPV’del ja BPVl kardinaalselt erinev. 
BPV puhul on näidatud et kokku 12st E2 seondumiskohast viiruse genoomi 
regulatoorses osas on 6 minimaalselt vajalikud selleks, et viiruse DNA saaks 
päranduda tütarrakku. HPV’del on regulatoorses alas üleüldse kokku 4 E2 
seondumiskohta. Meie uurimustööst selgus, et HPV-18 puhul on lisaks E2 val-
gule vaja minimaalselt 2 E2 seondumiskohta, et tagada DNA pärandumine 
tütarrakkudesse. Me näitasime, et suurenenud jaotumisfunktsiooni võimekus 
tuleneb E2 suurenenud kooperatiivse seondumise võimekusest antud järjestus-
tele. Lisaks näitasime me kui oluline on E2 seondumiskohtade täpne paigutus ja 
kontekst genoomis viiruse elutsükli jaoks. Mutatsioonanalüüs E2 seondumis-
kohtade vahelises alas osutas, et see element on evolutsiooni käigus optimee-
ritud viiruse genoomi tasakaalustatud transkriptsiooniks, replikatsiooniks ja 
segregeerumiseks.  
Kokkuvõtvalt me kirjeldame antud töö käigus uudset rakulist mudelsüs-
teemi, mis on sobilik HPV alasteks uurimustöödeks ning lähme sügavuti jagu-
nevates rakkudes viiruse DNA säilumise mehhanismide uurimisse, kus me defi-
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